Ocular Therapeutix, Inc. (OCUL) News
Filter OCUL News Items
OCUL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OCUL News Highlights
- OCUL's 30 day story count now stands at 5.
- Over the past 12 days, the trend for OCUL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DEC and EYE are the most mentioned tickers in articles about OCUL.
Latest OCUL News From Around the Web
Below are the latest news stories about OCULAR THERAPEUTIX INC that investors may wish to consider to help them evaluate OCUL as an investment opportunity.
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesBEDFORD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the closing of its previously announced underwritten public offering of 35,420,000 shares of its common stock at a public offering price of $3.25 per share, which includes 4,620,000 shares issued upon the exercise in full |
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 72% Price Boost Is Out Of Tune With RevenuesOcular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders would be excited to see that the share price has had a great... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day off right with a look at the biggest pre-market stock movers to watch for Thursday morning! |
Ocular Therapeutix™ Announces Pricing of Public Offering of Common StockBEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 30,800,000 shares of its common stock at a public offering price of $3.25 per share for gross proceeds of $100.1 million, before deducting underwriting discounts and commi |
Ocular Therapeutix™ Announces Proposed Public Offering of Common StockBEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number o |
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) large institutional owners must be happy as stock continues to impress, up 56% over the past weekKey Insights Significantly high institutional ownership implies Ocular Therapeutix's stock price is sensitive to their... |
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Call TranscriptOcular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Call Transcript November 7, 2023 Ocular Therapeutix, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.27. Operator: Good day. Thank you for standing by. Welcome to the Third Quarter 2023 Ocular Therapeutix Earnings Conference Call. At this time, all participants are in a listen-only mode. After […] |
Ocular Therapeutix™ to Present at Three Upcoming Investor ConferencesBEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: Jefferies London Healthcare ConferenceFireside Chat Date: Wednesday, November 15, 2023Fireside Chat Time: 3:00 PM GMTLocation: Waldorf Hilton, London, UK BTIG 3rd Annual Ophthalmology D |
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate UpdateFDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line Data from U.S.-based HELIOS Trial Evaluating AXPAXLI for Treatment of Non-Proliferative Diabetic Retinopathy Anticipated to be Presented in in Q2 2024 Top-line Data from U.S.-based Phase 2 Clinical Trial of OTX-TIC for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Anticipated to be Presented at ASCRS Meeting in Early |
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMDThe first subject expected to be dosed by year-end Company announces OTX-TKI trade name AXPAXLI BEDFORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced it had received written agreement regarding the overall design from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assess |